The Latest Breaking News from GSK

The aging global population and the growing demand for drugs and therapies to treat chronic diseases are boosting the long-term prospects of the pharmaceutical industry. Amid this backdrop, value investors could consider buying fundamentally strong pharma stocks GSK plc (GSK), Horizon Therapeutics (HZNP), and Neurocrine Biosciences (NBIX), as they are…

The Medicines and Healthcare products Regulatory Agency (MHRA) approved GSK’s jab, known as Arexvy, for use among older adults in July.

The turmoil at NatWest, half-year figures by Lloyds and profit upgrades at GSK and Rolls-Royce are just some of today’s big blue-chip developments.

The GSK team was excited to learn about the growth of the Lifesciences sector in Telangana and how global companies are leveraging the ecosystem.

The UK’s former chief scientific adviser, a familiar face during Covid, talks about his new role as chair of the London museum and putting its collection at the heart of our climate response

Exclusive: Consumer healthcare firm Haleon to cut hundreds of roles in UK and potentially thousands globally

RSV (respiratory syncytial virus) leads to around 8,000 deaths among people aged over 60 in the UK every year.

RSV (respiratory syncytial virus) leads to around 8,000 deaths among people aged over 60 in the UK every year.

The vaccine will help cut up to 175,000 GP visits